Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
32
IGC Quote, Financials, Valuation and Earnings
Last price:
$0.37
Seasonality move
:
16.78%
Day range:
$0.33 - $0.38
52-week range:
$0.27 - $0.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.17x
P/B ratio:
3.98x
Volume:
728.3K
Avg. volume:
423.3K
1-year change:
28.04%
Market cap:
$29.4M
Revenue:
$1.3M
EPS (TTM):
-$0.18
Analysts' Opinion
-
Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, IGC Pharma has an estimated upside of 889.45% from its current price of $0.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.38.
Fair Value
-
According to the consensus of 0 analysts, IGC Pharma has 889.45% upside to fair value with a price target of -- per share.
IGC vs. S&P 500
-
Over the past 5 trading days, IGC Pharma has underperformed the S&P 500 by -6.58% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IGC Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IGC Pharma has grown year-over-year revenues for 1 quarter straight. In the most recent quarter IGC Pharma reported revenues of $412K.
Earnings Growth
-
IGC Pharma has grown year-over-year earnings for 1 quarter straight. In the most recent quarter IGC Pharma reported earnings per share of -$0.02.
Enterprise value:
27.9M
EV / Invested capital:
3.72x
Price / LTM sales:
22.17x
EV / EBIT:
--
EV / Revenue:
23.62x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$665K
Return On Assets:
-107.19%
Net Income Margin (TTM):
-1062.47%
Return On Equity:
-137.43%
Return On Invested Capital:
-135.4%
Operating Margin:
-427.19%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $678K | $1.3M | $1.2M | $291K | $412K | |
| Gross Profit | $407K | $594K | $665K | $174K | $198K | |
| Operating Income | -$14.2M | -$10.9M | -$9.3M | -$2.5M | -$1.8M | |
| EBITDA | -$13.5M | -$10.3M | -$8.7M | -$2.3M | -$1.6M | |
| Diluted EPS | -$0.27 | -$0.21 | -$0.18 | -$0.05 | -$0.02 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.7M | $21.7M | $11.2M | $6.1M | $4.3M | |
| Total Assets | $26.3M | $33.8M | $22M | $16.5M | $10.4M | |
| Current Liabilities | $1.9M | $2M | $1.4M | $2.1M | $2.8M | |
| Total Liabilities | $2.7M | $2.6M | $1.8M | $2.4M | $3M | |
| Total Equity | $23.6M | $31.3M | $20.1M | $14.1M | $7.4M | |
| Total Debt | $580K | $149K | $142K | $139K | $135K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.2M | -$6.3M | -$4.9M | -$1.6M | -$996K | |
| Cash From Investing | -$578K | -$192K | -$580K | $72K | -$65K | |
| Cash From Financing | $99K | $2.9M | $4M | $2.9M | $794K | |
| Free Cash Flow | -$7.9M | -$6.9M | -$5.5M | -$1.7M | -$1.1M | |
IGC
Sector
Market Cap
$29.4M
$43.9M
Price % of 52-Week High
41.65%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-12.13%
-0.74%
1-Year Price Total Return
28.04%
-29.11%
Beta (5-Year)
1.288
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.38
200-day SMA
Sell
Level
$0.42
Bollinger Bands (100)
Sell
Level
0.35 - 0.41
Chaikin Money Flow
Sell
Level
-458.7M
20-day SMA
Buy
Level
$0.37
Relative Strength Index (RSI14)
Buy
Level
52.47
ADX Line
Sell
Level
10.68
Williams %R
Neutral
Level
-47.7223
50-day SMA
Sell
Level
$0.38
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
1.3B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.8333)
Sell
CA Score
(Annual)
Level (-2.2153)
Buy
Beneish M-Score
(Annual)
Level (-6.4917)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (11.9371)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer’s. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Stock Forecast FAQ
In the current month, IGC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IGC average analyst price target in the past 3 months is --.
-
Where Will IGC Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that IGC Pharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About IGC Pharma?
Analysts are divided on their view about IGC Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IGC Pharma is a Sell and believe this share price will drop from its current level to --.
-
What Is IGC Pharma's Price Target?
The price target for IGC Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IGC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IGC Pharma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IGC?
You can purchase shares of IGC Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IGC Pharma shares.
-
What Is The IGC Pharma Share Price Today?
IGC Pharma was last trading at $0.37 per share. This represents the most recent stock quote for IGC Pharma. Yesterday, IGC Pharma closed at $0.38 per share.
-
How To Buy IGC Pharma Stock Online?
In order to purchase IGC Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
